一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Giredestrant；Fulvestrant or an Aromatase Inhibitor (Physician Choice)；LHRH Agonist，当前状态为研究进行中，已停止招募。登记地点显示中国长春、广州、临沂、南昌等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Giredestrant；Fulvestrant or an Aromatase Inhibitor (Physician Choice)；LHRH Agonist · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Hospital of Jilin University · 长春
- Sun Yet-sen University Cancer Center · 广州
- Linyishi Cancer Hospital · 临沂
- The Third Hospital of Nanchang · 南昌
- Fudan University Shanghai Cancer Center · 上海
- Tianjin Cancer Hospital · 天津
- Hubei Cancer Hospital · 武汉
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University · 西安
- Zhejiang Cancer Hospital · 浙江省
公开的入选条件
- * Women who are postmenopausal or premenopausal/perimenopausal
- * For women who are premenopausal or perimenopausal and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy for the duration of study treatment
- * Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent
- * Documented ER-positive tumor and HER2-negative tumor, assessed locally
- * Disease progression after treatment with one or two lines of systemic therapy (but not more than one prior targeted therapy) in the locally advanced or metastatic setting
- * Measurable disease as defined per RECIST v.1.1 or bone only disease which must have at least one predominantly lytic bone lesion confirmed by CT or MRI which can be followed
- * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- * Adequate organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04576455；登记信息更新于 2026-09-11。